Bone Biologics (BBLG) Stock Price, News & Analysis

Company Overview

Bone Biologics, Inc. (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects. Early-stage clinical studies and preclinical investigations are underway to assess safety, tolerability and preliminary efficacy in these high-need segments. The company collaborates with leading orthopedic surgeons and academic centers to design protocols and gather real-world insights that may inform future pivotal trials.

Founded in the late 2010s and headquartered in New Jersey, Bone Biologics has assembled a leadership team with extensive experience in regenerative medicine, cell therapy manufacturing and orthopedic clinical development. The company maintains partnerships with contract development and manufacturing organizations to scale its cell production processes, while engaging regulatory consultants to support filings with health authorities. As a dedicated cell therapy innovator, Bone Biologics aims to address significant unmet needs in bone repair and establish new standards for patient outcomes in orthopedic care.

Key Stats

• Today's Range: $1.01 to $1.09
• 50-Day Range: $1.07 to $1.47
• 52-Week Range: $1.01 to $4.13
• Volume: 80,561 shs
• Average Volume: 39,071 shs
• Market Capitalization: $1.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Bone Biologics Stock Analysis - MarketRank™

Bone Biologics scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Bone Biologics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Bone Biologics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Bone Biologics are expected to grow in the coming year, from ($1.17) to ($0.64) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bone Biologics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bone Biologics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bone Biologics has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.55% of the float of Bone Biologics has been sold short.

Short Interest Ratio / Days to Cover

Bone Biologics has a short interest ratio ("days to cover") of 0.37, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bone Biologics has recently decreased by 60.52%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bone Biologics does not currently pay a dividend.

Dividend Growth

Bone Biologics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.96

News Sentiment

Bone Biologics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Bone Biologics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bone Biologics insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.60% of the stock of Bone Biologics is held by insiders.

Percentage Held by Institutions

34.30% of the stock of Bone Biologics is held by institutions.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 7/27/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BBLG
• Previous Symbol: NASDAQ:BBLG
• CIK: 1419554
• Web: www.bonebiologics.com
• Phone: 781-552-4452
• Fax: N/A
• Employees: 2
• Year Founded: 2004

Profitability

• EPS (Trailing Twelve Months): ($2.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.11 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -50.47%
• Return on Assets: -47.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.11
• Quick Ratio: 16.11

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.00 per share
• Price / Book: 0.34

Miscellaneous

• Outstanding Shares: 1,810,000
• Free Float: 1,709,000
• Market Cap: $1.86 million
• Optionable: Not Optionable
• Beta: 0.90